Nasal congestion due to allergic rhinitis

- Healthy male or female volunteers must be 18 to 60 years old.
- Subjects must currently use or have previously used oral decongestant products.
- Subjects must have a documented and/or self-reported history (of at least 2 years) of allergic rhinitis with nasal congestion.
- Subjects must be willing to stop use of current decongestant and allergy medications during the study, and for the number of wash-out days required for their medication prior to the runin
period.
- Subjects must have nasal congestion due to allergic rhinitis of at least mild severity (sign/symptom clearly present, but minimal awareness; easily tolerated) at Visits 1 and 2.
- Subjects must have a mean seated (after 5 minutes of rest) systolic/diastolic blood pressure ≤ 138/88 mmHg.
- Subjects must have normal or clinically acceptable physical exam.
- Subjects must agree not to take monoamine oxidase inhibitor (MAOI) for 14 days before study participation and 14 days after the end of the study.
- Subjects must be willing to give written informed consent (prior to any study related procedures being performed) and able to adhere to restrictions and examination schedules.
- Female subjects of childbearing potential (a non-menopausal female who has not had a hysterectomy, bilateral oophorectomy, or medically documented ovarian failure, including a young woman who has not yet started menstruating) must be using medically acceptable (documented failure rate of less than 1%) birth control measures. Examples of medically acceptable contraception include hormonal contraceptives, intrauterine device (IUD), double-barrier method (any combination of male or female condom, diaphragm, spermicidal gel, sponge) or sterilization.

- Subjects must not have any significant medical condition which, in the judgment of the investigator, is a contraindication to the use of phenylephrine HCl, might interfere with the study or requires treatment expected to affect the blood pressure. These may include thyroid disease (e.g. hyperthyroidism, hypothyroidism), uncontrolled diabetes mellitus, coronary heart disease, ischemic heart disease, elevated intraocular pressure, prostatic hypertrophy, etc.
- Subjects that have received allergen immunotherapy (if less than 3 months of stable dosing prior to screening) or Xolair (omalizumab) therapy within the past two years.
- Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to treatment administration.
- Subjects who have participated in a clinical trial of an investigational treatment within 30 days prior to the start of the study.
- Subjects who are, appear to be, or are known to be, current or former addicts or alcoholics.
- Subjects who have a known allergy or intolerance to phenylephrine HCl or any other decongestant, or any ntihistamine.
- Females who are pregnant, nursing or unwilling to use/practice medically acceptable contraception (documented failure rate of less than 1%).
- Subjects who have used a nasal decongestant or phenylephrine-containing product other than study medication after the start of the study and during the washout period.
- Subjects with a history of asthma, rhinitis medicamentosa, or presenting with acute or chronic sinusitis.
- Subjects that have used inhaled, oral, rectal, topical (intranasal corticosteroids for allergic rhinitis are permitted), intramuscular, and/or intravenous chronic or intermittent corticosteroids (up to 1% topical hydrocortisone is permitted).
- Subject who have family or who currently or previously have been employed in the pharmaceutical industry.